Combination Therapy for Pancreatic Cancer

胰腺癌的联合治疗

基本信息

  • 批准号:
    10581174
  • 负责人:
  • 金额:
    $ 47.26万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-04-01 至 2028-03-31
  • 项目状态:
    未结题

项目摘要

ABSTRACT: Pancreatic cancer (PCa) is one of the deadliest forms of cancers and the fourth leading cause of cancer deaths in the United States. Combination of gemcitabine (GEM) and paclitaxel (PTX) or Nab-paclitaxel (nanoparticle (NP) albumin-bound PTX, Abraxane®) is one of the first-line treatments for locally recurrent or metastatic PCa. However, only limited benefits have been shown in clinic. In addition, this treatment is associated with significant toxicity. PCa is characterized by the presence of dense stroma that may limit effective penetration of relatively large-sized NPs. On the other hand, free GEM is rapidly eliminated from the blood circulation and is also subjected to rapid inactivation by deaminase. Therefore, there is an urgent need to develop small NPs that are capable of protecting the drugs and are effective in tumor accumulation and penetration. We have recently shown that conjugation of GEM to POEG-co-PVD polymer led to a significant decrease in the particle size from 160 to 13 nm. The resulting nanocarrier, named PGEM, was highly effective in tumor accumulation and penetration. As a GEM prodrug, PGEM showed significantly improved antitumor activity in vivo. In addition, PGEM is highly effective in codelivery of GEM and another hydrophobic drug such as PF-04136309 (PF), a CCR2 antagonist. Flow study showed that PGEM treatment also led to increased CD8+ T cell response. However, we also observed increased numbers of myeloid-derived suppressor cells (MDSCs). Mechanistic study showed upregulation of CCL2 and CCL7 following treatment with PGEM. CCL2 and CCL7 are known to act on CCR2 on tumor cells and immune cells and promote tumor invasion and metastasis through both direct impact on tumor cells and recruitment of immunosuppressive cells. Our preliminary data showed that incorporation of PF into PGEM NPs led to significant improvement in PANC02 model. More importantly this treatment resulted in a drastic improvement in tumor immune microenvironment, which boded well with combination with anti-PD-1 treatment. This application is focused on further improvement and characterization of PF/PGEM-based therapy. An improved PGEM (PGEMi) will also be developed to improve the bioavailability of both PF and PGEM in tumor tissues. Three specific aims will be pursued in this application: Aim 1 will develop and characterize PGEMi and PF/PGEMi with respect to biophysical and in vitro biological properties. Aim 2 will define the tumor penetration efficiency of PGEMi, and the PK and biodistribution of PF/PGEMi in murine and human PCa models including PDX model.Aim 3 will investigate the toxicity profile and the therapeutic efficacy of PF/PGEMi in various PCa models. Completion of this study may lead to the development of a new and improved combination therapy that will advance the treatment of PCa.
摘要: 胰腺癌是最致命的癌症之一,也是导致癌症死亡的第四大原因。 在美国。吉西他滨(GEM)与紫杉醇(PTX)或NAB-紫杉醇(纳米粒)的组合 (NP)白蛋白结合PTX,Abraxane®)是局部复发或转移性前列腺癌的一线治疗方法之一。 然而,在临床上仅显示出有限的益处。此外,这种治疗与显著的 毒性。前列腺癌的特点是存在致密的间质,这可能限制相对有效的穿透。 大型核动力源。另一方面,游离宝石迅速从血液循环中消除,也 被脱氨酶迅速失活的。因此,迫切需要开发符合以下条件的小型核燃料 能够保护药物,并有效地促进肿瘤的蓄积和渗透。我们最近展示了 GEM与POEg-co-PVD聚合物的偶联使其粒径从160降至 13 nm。由此产生的纳米载体,名为PGEM,在肿瘤聚集和渗透方面非常有效。 作为一种GEM前药,PGEM体内抗肿瘤活性显著增强。此外,PGEM具有很高的 有效地将GEM与另一种疏水药物,如CCR2拮抗剂PF-04136309(PF)共传递。 Flow研究显示,经PGEM处理后,CD8+T细胞应答增加。但是我们也观察到, 髓系来源的抑制细胞(MDSCs)数量增加。机械学研究表明, 经PGEM处理后的CCL2和CCL7。已知CCL2和CCL7作用于肿瘤细胞上的CCR2和 免疫细胞通过直接作用于肿瘤细胞和促进肿瘤侵袭转移 免疫抑制细胞的招募。我们的初步数据显示,PF被掺入PGEM NPs中 导致了PANC02模型的显著改进。更重要的是,这种治疗导致了一场激烈的 肿瘤免疫微环境的改善,与抗PD-1治疗相结合是个好兆头。 这一应用的重点是基于PF/PGEM治疗的进一步改进和表征。一个 还将开发改进的PGEM(PGEMi),以提高PF和PGEM在肿瘤中的生物利用度 纸巾。本申请将追求三个具体目标:目标1将开发和表征PGEMi和 PF/PGEMi的生物物理和体外生物学特性。目标2将定义肿瘤的穿透性 PGEMi的效率,以及pF/pGEMi在小鼠和人前列腺癌模型中的PK和生物分布 PDX模型。AIM 3将研究PF/PGEMi在各种PCa中的毒性分布和治疗效果 模特们。这项研究的完成可能会导致开发一种新的、改进的联合疗法, 将推进前列腺癌的治疗。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Song Li其他文献

Song Li的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Song Li', 18)}}的其他基金

Nanoparticles-mediated combination therapy for breast cancer
纳米颗粒介导的乳腺癌联合疗法
  • 批准号:
    10617544
  • 财政年份:
    2023
  • 资助金额:
    $ 47.26万
  • 项目类别:
Mechanopriming for cell engineering
用于细胞工程的机械引发剂
  • 批准号:
    10737574
  • 财政年份:
    2023
  • 资助金额:
    $ 47.26万
  • 项目类别:
Multimodal wireless electrical stimulation for tissue regeneration
用于组织再生的多模式无线电刺激
  • 批准号:
    10615764
  • 财政年份:
    2022
  • 资助金额:
    $ 47.26万
  • 项目类别:
Study of Interleukin 33 as a new immunotherapy of lung cancer
白细胞介素33作为肺癌新型免疫疗法的研究
  • 批准号:
    10703786
  • 财政年份:
    2022
  • 资助金额:
    $ 47.26万
  • 项目类别:
Regulation of cell reprogramming by matrix stiffness
通过基质硬度调节细胞重编程
  • 批准号:
    10281141
  • 财政年份:
    2021
  • 资助金额:
    $ 47.26万
  • 项目类别:
Regulation of cell reprogramming by matrix stiffness
通过基质硬度调节细胞重编程
  • 批准号:
    10491279
  • 财政年份:
    2021
  • 资助金额:
    $ 47.26万
  • 项目类别:
Regulation of cell reprogramming by matrix stiffness
通过基质硬度调节细胞重编程
  • 批准号:
    10687264
  • 财政年份:
    2021
  • 资助金额:
    $ 47.26万
  • 项目类别:
Study of Interleukin 33 as a new immunotherapy of lung cancer
白细胞介素33作为肺癌新型免疫疗法的研究
  • 批准号:
    10442707
  • 财政年份:
    2019
  • 资助金额:
    $ 47.26万
  • 项目类别:
Study of Interleukin 33 as a new immunotherapy of lung cancer
白细胞介素33作为肺癌新型免疫疗法的研究
  • 批准号:
    10202507
  • 财政年份:
    2019
  • 资助金额:
    $ 47.26万
  • 项目类别:
Platelets-Mediated Delivery of Checkpoint Inhibitors for Post-Surgical Cancer Immunotherapy
用于术后癌症免疫治疗的血小板介导的检查点抑制剂递送
  • 批准号:
    10668316
  • 财政年份:
    2019
  • 资助金额:
    $ 47.26万
  • 项目类别:

相似海外基金

Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
  • 批准号:
    10735090
  • 财政年份:
    2023
  • 资助金额:
    $ 47.26万
  • 项目类别:
The ESCAPE clinical trial of circulating tumor DNA to guide adjuvant therapy in chemo-resistant triple negative breast cancer
循环肿瘤 DNA 指导化疗耐药三阴性乳腺癌辅助治疗的 ESCAPE 临床试验
  • 批准号:
    494901
  • 财政年份:
    2023
  • 资助金额:
    $ 47.26万
  • 项目类别:
    Operating Grants
A Type I Hybrid Effectiveness-Implementation Trial to Evaluate a Navigation-Based Multilevel Intervention to Decrease Delays Starting Adjuvant Therapy Among Patients with Head and Neck Cancer
一项 I 型混合有效性实施试验,用于评估基于导航的多级干预措施,以减少头颈癌患者开始辅助治疗的延迟
  • 批准号:
    10714537
  • 财政年份:
    2023
  • 资助金额:
    $ 47.26万
  • 项目类别:
Multi-modal machine learning to guide adjuvant therapy in surgically resectable colorectal cancer
多模式机器学习指导可手术切除结直肠癌的辅助治疗
  • 批准号:
    10588103
  • 财政年份:
    2023
  • 资助金额:
    $ 47.26万
  • 项目类别:
Efficacy of ethanol adjuvant therapy after resection of malignant soft tissue tumors
恶性软组织肿瘤切除术后乙醇辅助治疗的疗效
  • 批准号:
    22K09407
  • 财政年份:
    2022
  • 资助金额:
    $ 47.26万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Identification of immune response cells and development of novel adjuvant therapy for sublingual immunotherapy
免疫应答细胞的鉴定和舌下免疫治疗新型辅助疗法的开发
  • 批准号:
    21KK0287
  • 财政年份:
    2022
  • 资助金额:
    $ 47.26万
  • 项目类别:
    Fund for the Promotion of Joint International Research (Fostering Joint International Research (A))
Pursuing molecular biomarkers to guide adjuvant therapy for HPV+ head and neck cancers after transoral robotic surgery
寻找分子生物标志物来指导经口机器人手术后 HPV 头颈癌的辅助治疗
  • 批准号:
    10357120
  • 财政年份:
    2022
  • 资助金额:
    $ 47.26万
  • 项目类别:
Biomarker research using two prospective studies on preoperative and postoperative adjuvant therapy for pancreatic cancer
使用两项关于胰腺癌术前和术后辅助治疗的前瞻性研究进行生物标志物研究
  • 批准号:
    21K08700
  • 财政年份:
    2021
  • 资助金额:
    $ 47.26万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Personalized Resistant Starch as an Adjuvant Therapy for Pediatric Inflammatory Bowel Disease
个性化抗性淀粉作为小儿炎症性肠病的辅助治疗
  • 批准号:
    437315
  • 财政年份:
    2020
  • 资助金额:
    $ 47.26万
  • 项目类别:
    Studentship Programs
Tailored adjuvant therapy in POLE-mutated and p53-wildtype early stage endometrial cancer (TAPER)
POLE 突变和 p53 野生型早期子宫内膜癌 (TAPER) 的定制辅助治疗
  • 批准号:
    435603
  • 财政年份:
    2020
  • 资助金额:
    $ 47.26万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了